PF-Atlas › Clinical Trials › NCT00534079
Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
Dornase alfa · Phase 3
Registry ID
NCT00534079
Phase
Phase 3
Status
Completed
Drug / intervention
Dornase alfa (Pulmozyme)
Sponsor
University of Jena
Start
2007-09
Enrollment
23
Locations
2
About this trial
Rhinosinusitis disorders are often associated with Cystic Fibrosis. They can restrict quality of life enormously and give cause to repeated ENT surgery. The basic defect in CF is a dysfunction of chloride channels in exocrine glands, leading to retention of secretions and consecutive chronic inflammation with bacterial superinfections. The prospective placebo controlled cross-over study aims at the evaluation of a nasally inhalation of Pulmozyme with respect to mucus retention and resulting inflammation.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00534079 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.